Spherusol Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to improved understanding of coccidioidomycosis epidemiology, historical reliance on serological diagnostics, expansion of public health screening initiatives, increased research on fungal pathogens, availability of standardized diagnostic reagents.

The growth in the forecast period can be attributed to growing investment in infectious disease surveillance, rising demand for early exposure detection tools, expansion of diagnostic testing in endemic regions, increasing research into immune response diagnostics, broader adoption of preventive healthcare diagnostics. Major trends in the forecast period include increasing adoption of advanced diagnostic skin tests, rising focus on early immune response detection, growing use of dth-based diagnostic tools, expansion of fungal infection surveillance programs, enhanced clinical emphasis on epidemiological screening.

The rising incidence of coccidioidomycosis (Valley fever) is expected to drive the growth of the Spherusol market. Coccidioidomycosis is a fungal infection caused by the Coccidioides fungus, which thrives in dry, sandy soils and primarily affects the lungs but can spread to other parts of the body through inhalation of spores. The incidence of this disease is increasing due to factors such as climate change, which creates warmer and drier conditions favorable for fungal growth, and population growth in endemic regions, leading to greater human exposure. Spherusol supports the diagnosis of coccidioidomycosis through a skin test that detects hypersensitivity to Coccidioides immitis by measuring the reaction at the injection site after 48 hours. For instance, in August 2025, the California Department of Public Health reported over 5,500 provisional Valley fever cases in the first half of 2025, following nearly 12,500 cases in 2024, highlighting a sustained upward trend. Therefore, the rising incidence of coccidioidomycosis is driving the Spherusol market.

The rise in the aging population is expected to propel the Spherusol market. The aging population, consisting of individuals aged 65 and older, is growing due to improved healthcare, better living standards, and medical advancements that increase life expectancy. Older adults are more susceptible to immune system changes and conditions that require targeted care. Spherusol is relevant for this population as it aids in managing immune responses, improving diagnosis, and facilitating preventive care. For instance, in January 2024, the Population Reference Bureau reported that the number of Americans aged 65 and older is projected to rise from 58 million in 2022 to 82 million by 2050, a 47% increase, raising their share of the total U.S. population from 17% to 23%. Therefore, the growing aging population is driving the Spherusol market.

The rise in outdoor activities is also expected to propel the Spherusol market. Outdoor activities, including recreational and physical pursuits in open spaces, are increasing as people seek exercise, mental well-being, and a break from technology. Greater participation in outdoor activities increases exposure to allergens and environmental pathogens, making immune testing and monitoring more important. Spherusol helps manage such exposures by detecting hypersensitivity reactions and guiding preventive care. For instance, in June 2024, the Outdoor Industry Association reported that outdoor recreation participation reached an all-time high of 175.8 million people in 2023, up 4.1% from the previous year, representing 57.3% of the U.S. population. Therefore, the rise in outdoor activities is driving the growth of the Spherusol market.

Major companies operating in the spherusol market are Nielsen Biosciences Inc.

North America was the largest region in the spherusol market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the spherusol market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spherusol market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the spherusol market by increasing costs of imported diagnostic reagents, laboratory consumables, testing kits, and controlled storage materials used in hypersensitivity skin testing. Diagnostic laboratories and healthcare systems in North America are most affected due to dependence on specialized imported components, while manufacturing and distribution costs rise in endemic regions. These tariffs are elevating procurement costs and limiting rapid scale-up of diagnostic programs. However, they are also encouraging localized reagent production, domestic diagnostic kit manufacturing, and regional supply chain resilience for essential diagnostic products.

The spherusol market research report is one of a series of new reports that provides spherusol market statistics, including spherusol industry global market size, regional shares, competitors with a spherusol market share, detailed spherusol market segments, market trends and opportunities, and any further data you may need to thrive in the spherusol industry. This spherusol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spherusol is a diagnostic skin test used to detect delayed-type hypersensitivity (DTH) reactions from exposure to Coccidioides fungi, which cause valley fever (coccidioidomycosis). The test assesses past infections and immune responses but is not intended for diagnosing active infections.

The primary indications for Spherusol include pain management, infection control, neurological disorders, and oncology. Pain management involves using treatments and diagnostic tools to alleviate chronic pain, which in the case of Spherusol can be associated with coccidioidomycosis, causing symptoms such as chest, joint, and muscle pain. It is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by hospitals, diagnostic laboratories, and research institutions.

The spherusol market consists of sales of skin test antigens, which include sterile solutions and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.